Rocket Pharmaceuticals
RCKT
96 hedge funds and large institutions have $736M invested in Rocket Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 48 increasing their positions, 16 reducing their positions, and 5 closing their positions.
340% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 5
334% more capital inflows, than outflows
Capital inflows: $142M | Capital outflows: $32.7M
200% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 16
19% more funds holding
Funds holding: 81 → 96 (+15)
2.47% more ownership
Funds ownership: 95.09% → 97.57% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
85% less call options, than puts
Call options by funds: $323K | Put options by funds: $2.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Perceptive Advisors
New York
|
+$26.5M |
| 2 |
Deerfield Management
New York
|
+$15M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$13.7M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$9.84M |
| 5 |
RTW Investments
New York
|
+$9.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$7.89M |
| 2 |
BM
Bridger Management
New York
|
-$4.92M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.23M |
| 4 |
UONDDL
University of Notre Dame du Lac
South Bend,
Indiana
|
-$3M |
| 5 |
Marshall Wace North America
New York
|
-$2.86M |
RCKT Hedge Fund Activity: Q2 2019 in Review
96 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2019, worth a combined $736M — down 2% from $751M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new RCKT positions and 5 closed out — a net gain of 17 holders — while 48 added to existing stakes and 16 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $26.5M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $7.89M sold.
- 96 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2019, up from 81 in Q1 2019.
- Funds reported $736M of Rocket Pharmaceuticals stock for Q2 2019, down 2% quarter-over-quarter.
- 22 funds opened new Rocket Pharmaceuticals positions in Q2 2019 and 5 closed out, a net change of +17 holders.
- The largest Rocket Pharmaceuticals buyer in Q2 2019 was Perceptive Advisors, an estimated $26.5M added.
- The largest Rocket Pharmaceuticals seller in Q2 2019 was EcoR1 Capital, an estimated $7.89M sold.
Based on aggregated 13F filings for Q2 2019.